News

Latest valve and structural heart intelligence

38 articles tagged FDA
Healio Cardiology
trial·9 days ago·Healio Cardiology

Device shows benefit in severe tricuspid regurgitation

The CLASP II TR trial randomized 450 patients with symptomatic severe tricuspid regurgitation to transcatheter tricuspid valve repair with the Pascal Precision system (Edwards Lifesciences) versus optimal medical therapy alone. At 1 year, the device improved health status and reduced TR severity compared with medical therapy, though no significant difference was observed in mortality or heart failure hospitalization.

Digest: This represents the first randomized controlled trial data for the FDA-approved Pascal Precision system in tricuspid regurgitation, providing evidence for transcatheter intervention in a valve position historically undertreated and associated with poor outcomes.

TTVREdwardsTrialFDARead original
CVB
trial·13 days ago·Cardiovascular Business

Medtronic studying safety, effectiveness of its self-expanding TAVR valves in patients with moderate AS

Medtronic has initiated a clinical study evaluating the safety and effectiveness of its self-expanding transcatheter aortic valve replacement (TAVR) systems in patients with moderate aortic stenosis. The trial represents an expansion into earlier-stage disease beyond current severe symptomatic AS indications.

Digest: This trial could potentially expand TAVR treatment paradigm to moderate AS patients, representing a significant market opportunity and earlier intervention strategy that would shift current guidelines recommending watchful waiting.

TAVRTrialMedtronicFDARead original
CVB
regulatory·17 days ago·Cardiovascular Business

FDA confirms new Class I recall for heart valve delivery system due to safety risk

The FDA has confirmed a new Class I recall for a heart valve delivery system due to identified safety risks. Class I recalls represent the most serious category, indicating reasonable probability that use of the product will cause serious adverse health consequences or death.

Digest: Class I recalls of transcatheter valve delivery systems can impact procedural planning, require device inventory checks, and may necessitate changes in implantation technique or device selection for structural heart teams.

CVB
research·18 days ago·Cardiovascular Business

New stroke prevention device for TAVR falls short, raising questions about the value of embolic protection

A new embolic protection device designed to prevent stroke during TAVR procedures failed to meet its clinical endpoints. The negative results call into question the overall clinical value and efficacy of embolic protection strategies in transcatheter aortic valve replacement.

Digest: This trial failure may influence adoption patterns of embolic protection devices in TAVR and could impact regulatory pathways and reimbursement decisions for this device class.

TAVRTrialFDARead original
DIC
trial·19 days ago·Diagnostic & Interventional Cardiology

Abbott Announces 30-day Clinical Trial Results for Coronary Intravascular Lithotripsy System

Abbott announced 30-day results from a clinical trial evaluating its coronary intravascular lithotripsy (IVL) system for treating calcified coronary artery lesions. The trial assessed safety and performance of the device in modifying severely calcified coronary lesions prior to stenting.

Digest: This represents Abbott's entry into the coronary IVL space, a market currently dominated by Shockwave Medical, and could expand treatment options for complex calcified coronary disease that structural heart teams encounter in TAVR and other transcatheter procedures.

AbbottTrialFDARead original
CVB
news·20 days ago·Cardiovascular Business

TAVR linked to key benefits for select heart patients with moderate aortic stenosis

Transcatheter aortic valve replacement (TAVR) demonstrated clinical benefits in selected patients with moderate aortic stenosis, expanding potential indications beyond current severe stenosis criteria. The findings suggest TAVR may benefit a broader patient population than currently approved.

Digest: This represents a potential paradigm shift in TAVR eligibility that could significantly expand the treatable patient population and market, though awaits definitive trial data and regulatory consideration.

TAVRTrialGuidelinesFDARead original
CVB
regulatory·25 days ago·Cardiovascular Business

FDA approves transcatheter device for treating PVL after heart surgery for first time

The FDA has granted first-time approval for a transcatheter device to treat paravalvular leak (PVL) following surgical valve replacement. This represents the first dedicated transcatheter solution approved for post-surgical PVL management.

Digest: This approval establishes a new minimally invasive treatment option for a complication that previously required redo surgery or off-label device use, addressing an unmet need in the post-surgical valve population.

FDASurgicalMinimally InvasiveRead original
Diagnostic & Interventional Cardiology
regulatory·25 days ago·Diagnostic & Interventional Cardiology

PVL Occluder Receives FDA Clearance

Abbott received FDA approval for the Amplatzer Paraclose PVL Occluder, the first transcatheter device specifically designed to treat paravalvular leak following surgical valve replacement. The approval was supported by the PARADIGM study, a prospective multicenter trial of 200 patients demonstrating effective minimally invasive closure of PVL as an alternative to repeat open-heart surgery.

Digest: This approval addresses a significant unmet need for the 5-17% of surgical valve replacement patients who develop paravalvular leak, providing the first purpose-built transcatheter solution to avoid repeat cardiac surgery.

FDAAbbottSurgicalMinimally InvasiveRead original
Diagnostic & Interventional Cardiology
regulatory·about 1 month ago·Diagnostic & Interventional Cardiology

FDA Approves Transcatheter Tricuspid Valve Repair System

The FDA approved Edwards Lifesciences' PASCAL Precision system for transcatheter edge-to-edge repair (T-TEER) in patients with symptomatic severe tricuspid regurgitation at intermediate or greater surgical risk. Additionally, the FDA approved the PASCAL Ace with Capture Clarity system for degenerative mitral TEER, featuring the first fluoroscopic indicators to confirm leaflet capture.

Digest: Edwards becomes the only company offering both transcatheter repair and replacement therapies for mitral and tricuspid valves in the U.S., expanding treatment options for TR patients and introducing novel fluoroscopic confirmation technology to simplify TEER procedures.

FDATTVRTMVREdwardsRead original
Healio Cardiology
regulatory·about 1 month ago·Healio Cardiology

FDA approves new tricuspid valve repair system

The FDA approved Edwards Lifesciences' PASCAL Precision system for transcatheter tricuspid valve repair in patients with symptomatic severe tricuspid regurgitation at elevated surgical risk despite optimal medical therapy. Approval was based on 1-year results from the CLASP TR trial of 65 patients demonstrating significant improvement in tricuspid regurgitation severity with durable outcomes.

Digest: This approval expands the transcatheter treatment options for severe tricuspid regurgitation in the US market, addressing a historically underserved patient population with limited therapeutic alternatives.

TTVRFDAEdwardsTrialRead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

FDA approves Pascal Precision system from Edwards Lifesciences for tricuspid valve repair

The FDA has approved Edwards Lifesciences' Pascal Precision system for transcatheter tricuspid valve repair. This represents regulatory clearance for Edwards' edge-to-edge repair platform to treat tricuspid regurgitation.

Digest: This approval provides interventional cardiologists with another transcatheter option for treating tricuspid regurgitation, expanding the competitive landscape in the emerging TTVR market.

TTVREdwardsFDARegulatoryRead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

FDA shares warning about Edwards Lifesciences heart valve tech after patient death

The FDA issued a safety warning regarding Edwards Lifesciences heart valve technology following a patient death. The agency is alerting healthcare providers and patients about potential safety concerns associated with the device.

Digest: FDA safety communications regarding transcatheter heart valve platforms can impact clinical decision-making, device utilization patterns, and inform risk-benefit discussions with patients undergoing valve interventions.

FDAEdwardsTAVRRead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

Physicians support Medicare coverage for TAVR in patients with aortic regurgitation

Physicians are advocating for Medicare coverage expansion to include transcatheter aortic valve replacement for patients with native aortic regurgitation. This represents a push to extend TAVR reimbursement beyond the currently covered indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that some operators are already performing with dedicated or adapted devices.

TAVRReimbursementFDARead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

JenaValve recalls certain TAVR delivery catheters over safety concerns

JenaValve has initiated a recall of certain delivery catheters used with its transcatheter aortic valve replacement system due to safety concerns. The specific nature of the safety issue and scope of affected devices were not detailed in the article.

Digest: Delivery catheter malfunctions during TAVR procedures can lead to procedural complications, deployment failures, or patient harm, making this recall clinically relevant for centers using JenaValve systems.

TAVRFDARegulatoryRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

CMS considers covering TAVR for aortic regurgitation

CMS is considering coverage for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. This would represent a significant expansion beyond the current approved indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that has shown feasibility in selected patients but lacks robust trial data.

TAVRReimbursementFDACMSRead original
Diagnostic & Interventional Cardiology
regulatory·about 2 months ago·Diagnostic & Interventional Cardiology

FDA Approves Surgical Pulmonary Valve for Pediatric Patients

The FDA approved Edwards Lifesciences' AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed for pediatric congenital heart disease patients that can be expanded transcatheter as the child grows. The pivotal study met primary endpoints with 100% freedom from device-related complications at 30 days, no reinterventions at 6 months, and at 1 year all patients maintained RVOT mean gradients ≤40 mmHg with less than moderate pulmonary regurgitation.

Digest: This approval addresses a significant unmet need in pediatric congenital heart disease by potentially reducing the number of repeat open-heart surgeries through transcatheter valve expansion, representing a paradigm shift in long-term care planning for this vulnerable population.

FDAEdwardsCongenitalSurgicalRead original
Healio Cardiology
regulatory·about 2 months ago·Healio Cardiology

FDA approves pediatric pulmonary valve that grows with patients

The FDA approved the Autus Size-Adjustable Valve from Edwards Lifesciences, the first pulmonary valve replacement designed to expand with patient growth, reducing repeat surgeries in pediatric congenital heart disease. The pivotal study of 62 patients aged 18 months to 16 years demonstrated 100% freedom from device-related complications at 30 days, no reinterventions at 6 months, and favorable hemodynamics through 1 year with mean RVOT gradients ≤40 mmHg and less than moderate regurgitation.

Digest: This first-in-class balloon-expandable valve (13-22 mm) with polymeric leaflets addresses a critical unmet need in pediatric congenital valve disease by potentially eliminating multiple open-heart surgeries during childhood growth.

FDAEdwardsCongenitalSurgicalRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

FDA approves first heart valve that grows with children

The FDA has approved the first pediatric heart valve prosthesis designed to grow with children as they develop. This represents a significant advancement in congenital valve replacement, potentially reducing the number of reoperations required in pediatric patients.

Digest: This approval addresses a critical unmet need in pediatric structural heart disease by eliminating the requirement for multiple valve replacements as children grow, which could substantially reduce surgical burden and improve long-term outcomes.

FDACongenitalSurgicalRead original
FDA Press Releases
regulatory·about 2 months ago·FDA Press Releases

FDA Approves First Heart Valve Designed to Grow with Children

The FDA approved the Autus Size-Adjustable Valve, the first surgically implanted pulmonary valve designed to expand with pediatric growth, featuring novel polymeric leaflets rather than bioprosthetic tissue. The valve can be initially implanted at 13mm diameter for toddlers and balloon-expanded up to 22mm as the child matures, potentially reducing the need for multiple open-heart reoperations.

Digest: This landmark approval addresses a significant unmet need in congenital heart disease management and introduces a novel biomaterial approach that could influence future pediatric valve development across multiple positions.

FDACongenitalSurgicalLeafletRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

FDA clears video endoscope for select minimally invasive cardiac surgeries

The FDA has granted clearance for a video endoscope system intended for use in select minimally invasive cardiac surgical procedures. Specific procedural indications and device specifications were not detailed in the available content.

Digest: Enhanced visualization technology for minimally invasive cardiac surgery may facilitate adoption of less invasive surgical approaches for structural heart interventions, particularly minimally invasive surgical valve repair and replacement.

FDASurgicalMinimally InvasiveImagingRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

FDA clears AI tool for detecting undiagnosed heart valve disease in ECGs

The FDA cleared an artificial intelligence tool designed to detect undiagnosed valvular heart disease through analysis of standard 12-lead electrocardiograms. The AI algorithm enables screening for structural heart conditions using routine ECG data without requiring echocardiography.

Digest: This screening tool could facilitate earlier identification of valve disease patients who may be candidates for structural heart interventions, potentially expanding the treatable patient population.

FDAImagingMarketRead original
CVB
regulatory·2 months ago·Cardiovascular Business

CMS finalizes sweeping TAVR changes, including Medicare coverage for asymptomatic patients

CMS finalized a national coverage determination expanding Medicare coverage for transcatheter aortic valve replacement to include asymptomatic patients with severe aortic stenosis. This represents a significant broadening of the Medicare eligible patient population beyond the previous requirement for symptomatic disease.

Digest: This reimbursement expansion substantially increases the addressable market for TAVR and aligns Medicare coverage with current clinical practice patterns and recent trial evidence in asymptomatic severe AS patients.

TAVRReimbursementFDALow RiskRead original
CVB
regulatory·2 months ago·Cardiovascular Business

FDA clears new device for capturing debris during TAVR

The FDA has granted clearance for a new embolic protection device designed to capture debris during transcatheter aortic valve replacement procedures. This device aims to reduce the risk of periprocedural stroke by preventing particulate matter from reaching the cerebral circulation during valve deployment.

Digest: Embolic protection devices address a persistent clinical concern in TAVR, as stroke remains a significant complication affecting 1-3% of procedures and impacting patient outcomes and healthcare costs.

FDATAVRRegulatoryRead original
CVB
news·3 months ago·Cardiovascular Business

‘This could be transformative’: Surgeon performs first US implant of heart valve still under FDA review

A cardiac surgeon performed the first US implant of an investigational heart valve device that is currently undergoing FDA review but has not yet received regulatory approval. The procedure represents an early access case under what is likely an FDA early feasibility study or expanded access protocol.

Digest: This signals advancement of a novel valve technology through US regulatory pathways and provides early clinical experience that may inform future FDA approval decisions and market adoption strategies.

FDATrialSurgicalRead original
Healio Cardiology
research·3 months ago·Healio Cardiology

Transcatheter repair wins for severe tricuspid regurgitation

The TRIC-I-HF trial demonstrated that transcatheter tricuspid valve repair plus optimal medical therapy was superior to medical therapy alone in patients with symptomatic severe tricuspid regurgitation and heart failure. The intervention reduced all-cause death and HF hospitalization with benefits emerging early and sustained to 3 years, along with meaningful quality of life improvements.

Digest: This represents the first time transcatheter tricuspid repair has shown significant reductions in hard clinical endpoints (mortality and HF hospitalization), not just quality of life, potentially establishing a new standard of care for severe tricuspid regurgitation patients.

TTVRTrialESCFDARead original
Diagnostic & Interventional Cardiology
industry·3 months ago·Diagnostic & Interventional Cardiology

Ventripoint Expands Subscription Access to AI Cardiac Imaging

Ventripoint Diagnostics is expanding subscription-based access to its FDA-cleared VMS+ 4.0 platform, which uses AI and Knowledge Based Reconstruction technology to generate MRI-comparable 3D volumetric measurements of all four cardiac chambers from standard echocardiographic images. The company is implementing a Device-as-a-Service model targeting approximately 80% subscription-based adoption to reduce capital budget barriers for hospital implementation.

Digest: This AI-powered echocardiographic platform addresses a critical need for accurate right ventricular volumetric assessment without requiring MRI, with subscription pricing potentially lowering adoption barriers for structural heart programs evaluating patients for interventions.

ImagingFDAMarketRead original
CVB
regulatory·3 months ago·Cardiovascular Business

FDA confirms new recall for Impella heart pump accessories

The FDA has confirmed a new recall affecting accessories used with Abiomed's Impella percutaneous ventricular assist device system. Specific details regarding the affected accessory components, reason for recall, and adverse event data were not provided in the available article content.

Digest: Impella devices are widely used for hemodynamic support during high-risk PCI and cardiogenic shock management, making any recall of associated accessories clinically relevant for procedural safety and device availability.

FDAAbbottHigh RiskRead original
Healio Cardiology
news·4 months ago·Healio Cardiology

DOJ’s $6.5B Medicaid sweep raises stakes on ‘honest mistakes’

The U.S. Department of Justice charged 455 defendants, including 90 physicians and licensed healthcare professionals, with over $6.5 billion in alleged Medicare and Medicaid fraud in a 2026 national enforcement sweep. Healthcare law experts emphasize the need to distinguish between intentional fraud and honest billing mistakes resulting from complex regulatory requirements, as federal investigations continue with CMS deferring over $1 billion in Medicaid payments pending documentation review.

Digest: Heightened federal fraud enforcement and compliance scrutiny may impact structural heart practices through increased billing audits, reimbursement delays, and pressure to document medical necessity for high-cost procedures like TAVR and mitral interventions.

FDAReimbursementMarketRead original
CVB
industry·4 months ago·Cardiovascular Business

Abbott gathering real-world data on FDA-approved TriClip system

Abbott is collecting real-world data on its TriClip transcatheter tricuspid valve repair system following FDA approval. The post-market data collection will provide insights into clinical outcomes and device performance outside of controlled trial settings.

Digest: Real-world evidence will be critical for understanding TriClip performance in broader patient populations and supporting clinical adoption in the emerging transcatheter tricuspid repair market.

TTVRAbbottFDARegulatoryRead original
Diagnostic & Interventional Cardiology
industry·4 months ago·Diagnostic & Interventional Cardiology

HOPPR Introduces New AI Model for Chest CT Exams

HOPPR launched its fifth AI foundation model, the EF Chest CT Narrative Model, which processes 3D chest CT volumes to generate narrative reports across pulmonary, mediastinal, cardiac, upper abdominal, osseous, and soft tissue regions. The model was trained on a large proprietary U.S. dataset with deliberate overrepresentation of serious conditions including aortic injury, pulmonary embolism, rib fractures, and pneumothorax.

Digest: This AI model offers potential automated assessment of cardiac and aortic anatomy on chest CT, which could support preprocedural planning and screening for structural heart interventions, though clinical validation data were not provided.

ImagingFDARead original
Diagnostic & Interventional Cardiology
regulatory·4 months ago·Diagnostic & Interventional Cardiology

ElectroWire Medical Gets FDA Nod for LightningWire Transseptal Puncture System

ElectroWire Medical received FDA 510(k) clearance for the LightningWire Transseptal Puncture System, a novel electrosurgical guidewire designed to create atrial septal defects for left-sided cardiac procedures. The 0.032-inch diameter system features proprietary insulation enabling low-power transseptal puncture while providing stiffness comparable to 0.035-inch guidewires, with compatibility across existing electrosurgical generators and transseptal introducers.

Digest: This device addresses a critical access step for multiple structural heart procedures including TMVR, LAAO, and atrial fibrillation ablation, potentially improving procedural efficiency and reducing costs through platform-agnostic compatibility.

FDATMVRMinimally InvasiveMarketRead original
CVB
regulatory·5 months ago·Cardiovascular Business

Medtronic recalls heart valve delivery system due to safety risk

Medtronic has issued a recall of a heart valve delivery system due to an identified safety risk. Specific details regarding the affected device model, nature of the safety concern, patient impact, and scope of the recall were not provided in the available content.

Digest: Device recalls can impact procedural planning and inventory management for structural heart programs, and may signal potential adverse events requiring vigilance in patients who received the affected system.

MedtronicFDATAVRRead original
CVB
regulatory·5 months ago·Cardiovascular Business

CMS proposes major TAVR changes, including Medicare coverage for asymptomatic patients

CMS has proposed expanding Medicare coverage for transcatheter aortic valve replacement (TAVR) to include asymptomatic patients with severe aortic stenosis. This represents a significant policy shift from current coverage criteria that require symptomatic presentation.

Digest: Expansion of Medicare coverage to asymptomatic severe AS patients could substantially increase the eligible TAVR population and accelerate treatment timing, potentially preventing symptom development and improving outcomes.

TAVRReimbursementFDARead original
CVB
regulatory·6 months ago·Cardiovascular Business

FDA clears first dedicated tricuspid surgical valve

The FDA has granted clearance for the first surgical valve specifically designed for tricuspid valve replacement. This represents the first dedicated tricuspid prosthesis approved for surgical implantation, addressing a previously unmet need in tricuspid valve disease management.

Digest: This approval provides cardiac surgeons with a purpose-built solution for tricuspid valve replacement, potentially improving outcomes compared to off-label use of mitral or aortic prostheses in the tricuspid position.

FDASurgicalRegulatoryRead original
CVB
news·6 months ago·Cardiovascular Business

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’

An advocacy group is calling on the Trump administration to change regulations or policies affecting transcatheter aortic valve replacement (TAVR) access, framing the issue as government interference in clinical decision-making. No specific policy changes, clinical data, or patient access barriers are detailed in the available content.

Digest: Potential regulatory or reimbursement policy changes could significantly impact TAVR utilization patterns and patient access, though the specific issues being advocated remain unclear from this brief report.

TAVRFDAReimbursementGuidelinesRead original
CVB
industry·6 months ago·Cardiovascular Business

Boston Scientific invests $1.5B in MiRus with option to buy its TAVR business

Boston Scientific invested $1.5 billion in MiRus with an option to acquire its transcatheter aortic valve replacement (TAVR) business. The strategic investment provides Boston Scientific access to MiRus's TAVR platform and optionality in the structural heart valve market.

Digest: This major investment signals Boston Scientific's intent to enter or expand in the TAVR market, potentially reshaping competitive dynamics currently dominated by Edwards and Medtronic.

TAVRBoston ScientificMarketFDARead original
CVB
news·7 months ago·Cardiovascular Business

Stroke prevention devices for TAVR fail to make an impact

Cerebral embolic protection devices designed to prevent stroke during transcatheter aortic valve replacement procedures have failed to demonstrate clinical benefit in trials and real-world use. Despite mechanistic rationale and debris capture evidence, these devices have not shown reduction in stroke rates or neurocognitive outcomes, limiting their adoption in routine TAVR practice.

Digest: The lack of clinical efficacy for stroke prevention devices leaves periprocedural stroke as an unresolved complication of TAVR, affecting patient counseling, procedural risk assessment, and development priorities for next-generation protective technologies.

TAVRTrialFDARead original
CVB
industry·7 months ago·Cardiovascular Business

FDA approves next-gen mitral valve from Medtronic

The FDA has approved Medtronic's next-generation mitral valve system for commercial use in the United States. Specific device details, indication, and pivotal trial data supporting the approval were not provided in the article.

Digest: FDA approval of a new mitral valve platform from a major manufacturer expands the structural heart toolset for treating mitral regurgitation and impacts competitive landscape in the rapidly evolving TMVR market.

FDATMVRMedtronicMarketRead original